Royal India Corporation Ltd vs Samsrita Labs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 31, 2026

Key Highlights

The Latest Trading Price of Royal India Corporation Ltd is ₹ 5.21 as of 30 Oct 15:30 . The P/E Ratio of Royal India Corporation Ltd changed from 9.1 on March 2025 to 0 on March 2024 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Samsrita Labs Ltd changed from 28.5 on March 2022 to 0 on March 2024 . This represents a CAGR of -100.00% over 3 years The Market Cap of Royal India Corporation Ltd changed from ₹ 98.52 crore on March 2025 to ₹ 0 crore on March 2024 . This represents a CAGR of -100.00% over 6 yearsThe Market Cap of Samsrita Labs Ltd changed from ₹ 20.73 crore on March 2025 to ₹ 22.01 crore on March 2024 . This represents a CAGR of 1.00% over 6 years The revenue of Royal India Corporation Ltd for the Jun '26 is ₹ 5.08 crore as compare to the Mar '26 revenue of ₹ 73.81 crore. This represent the decline of -93.12% The revenue of Samsrita Labs Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0.05 crore. This represent the decline of -100% The ebitda of Royal India Corporation Ltd for the Jun '26 is ₹ 2.42 crore as compare to the Mar '26 ebitda of ₹ 70.19 crore. This represent the decline of -96.55% The ebitda of Samsrita Labs Ltd for the Jun '26 is ₹ -0.31 crore as compare to the Mar '26 ebitda of ₹ -0.12 crore. This represent the growth of 158.33% The net profit of Royal India Corporation Ltd changed from ₹ -0.38 crore to ₹ 1.93 crore over 9 quarters. This represents a CAGR of NaN% The net profit of Samsrita Labs Ltd changed from ₹ -0.28 crore to ₹ -0.31 crore over 5 quarters. This represents a CAGR of 8.48% The Dividend Payout of Royal India Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Samsrita Labs Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Royal India Corporation Ltd

Royal India Corporation Limited, formerly known as Natraj Financial & Services Limited was incorporated in 1984 in the name and style of Natraj Commercial Enterprises Limited.
In October 2006, Company changed its name to Natraj Financial & Services Limited.
In September, 2008, the Company was taken over by existing promoters as per the rules & regulation of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) regulations, 1997 and was again renamed to Royal India Corporation Limited in 2011. The Company evolved from being financial Services Company to a highly proactive multi-dimensional conglomerate with business interests that include Infrastructure developers, Real estate, Trading & Broking of Shares & Securities.
The Company is also engaged in the wholesale trading of Gold Bullion, plain gold jewellery, gold coins, and medallions.

About Samsrita Labs Ltd

Samsrita Labs Limited was initially established as 'Dr Habeebullah Life Sciences Limited' on January 25, 1996.
The name of the Company was changed from Dr Habeebullah Life Sciences Limited to Samsrita Labs Limited on October 13, 2022.
Company, initially focused on three different verticals called, Stem cell related Hospitals, Molecular Diagnostics and R&D in New Drug Discovery but due to other reasons, aimed to shifting into Bio-pharma activities like Trading, Exports & Imports, manufacturing of Bulk drugs, APIs, Specialty drugs, R&D etc through joint ventures or associations or mergers or by its own.
The Company is engaged into the business of research & experimental development on natural sciences and engineering, including bio pharma and hospital services also. In 2017, the Company changed its Main Objects clauses by venturing into the business of Bio-Pharma and also entered the following areas like New Drug Discovery including New Molecular Entity (NME - Pro Drug); Clinical Research Organization (CRO) related activities; Stem Cell - Lab, Research and Therapy; Research and Development in Bio-technology; Consultancy Division and Pharmacy; Academic Services like Courses / Lectures / Seminars on Biotechnology, Pharma, Stem Cell Research and therapy, Clinical Research and animal studies etc.

FAQs for the comparison of Royal India Corporation Ltd and Samsrita Labs Ltd

Which company has a larger market capitalization, Royal India Corporation Ltd or Samsrita Labs Ltd?

Market cap of Royal India Corporation Ltd is 61 Cr while Market cap of Samsrita Labs Ltd is 25 Cr

What are the key factors driving the stock performance of Royal India Corporation Ltd and Samsrita Labs Ltd?

The stock performance of Royal India Corporation Ltd and Samsrita Labs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Royal India Corporation Ltd and Samsrita Labs Ltd?

As of October 31, 2026, the Royal India Corporation Ltd stock price is INR ₹5.21. On the other hand, Samsrita Labs Ltd stock price is INR ₹11.11.

How do dividend payouts of Royal India Corporation Ltd and Samsrita Labs Ltd compare?

To compare the dividend payouts of Royal India Corporation Ltd and Samsrita Labs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.